Hepatitis C virus and atherosclerosis: A legacy after virologic cure?

Clinics and Research in Hepatology and Gastroenterology

Volumn 41, Issue 1, 2017, Pages 25-30

  Bassendine, M F ^a,b   Nielsen, S U ^a   Bridge, S H ^a,c   Felmlee, D J ^a,d   Sheridan, D A ^a,d   Packard, C J ^e   Neely, R D ^f  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c NORTHUMBRIA UNIVERSITY   (United Kingdom)

^d PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; LIPID; LIPOPROTEIN; MICRORNA;

ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; ANTIVIRAL THERAPY; ATHEROGENESIS; ATHEROSCLEROSIS; AUTOIMMUNITY; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFLAMMATION; META ANALYSIS (TOPIC); METABOLIC DISORDER; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); SHORT SURVEY; VIROLOGY; VIRUS ETIOLOGY; VIRUS PARTICLE; VIRUS PATHOGENESIS; COMPLICATION; CORONARY ARTERY DISEASE; DISEASE EXACERBATION; HEPACIVIRUS; ISOLATION AND PURIFICATION; PATHOGENICITY; PROGNOSIS; RISK FACTOR; SEVERITY OF ILLNESS INDEX; VIRUS LOAD;

ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; HEPACIVIRUS; HEPATITIS C; HUMANS; PROGNOSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; VIRAL LOAD;

EID: 85006421152     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2016.09.008     Document Type: Short Survey

References (64)

1. [1] Boccara, F., Lang, S., Meuleman, C., Ederhy, S., Mary-Krause, M., Costagliola, D., et al. HIV and coronary heart disease: time for a better understanding. J Am Coll Cardiol 61:5 (2013), 511–523.
2. [2] Campbell, L.A., Rosenfeld, M.E., Infection and atherosclerosis development. Arch Med Res 46:5 (2015), 339–350.
3. [3] Ji, Y.N., An, L., Zhan, P., Chen, X.H., Cytomegalovirus infection and coronary heart disease risk: a meta-analysis. Mol Biol Rep 39:6 (2012), 6537–6546.
4. [4] Ridker, P.M., LDL cholesterol: controversies and future therapeutic directions. Lancet 384:9943 (2014), 607–617.
5. [5] Kostis, W.J., How low an LDL-C should we go with statin therapy?. Curr Atheroscler Rep, 16(2), 2014, 388.
6. [6] Bassendine, M.F., Sheridan, D.A., Bridge, S.H., Felmlee, D.J., Neely, R.D., Lipids and HCV. Semin Immunopathol 35:1 (2013), 87–100.
7. [7] Paul, D., Madan, V., Bartenschlager, R., Hepatitis C virus RNA replication and assembly: living on the fat of the land. Cell Host Microbe 16:5 (2014), 569–579.
8. [8] Ampuero, J., Romero-Gomez, M., Assessing cardiovascular risk in hepatitis C: an unmet need. World J Hepatol 7:19 (2015), 2214–2219.
9. [9] Vassalle, C., Masini, S., Bianchi, F., Zucchelli, G.C., Evidence for association between hepatitis C virus seropositivity and coronary artery disease. Heart 90:5 (2004), 565–566.
10. [10] Roed, T., Lebech, A.M., Kjaer, A., Weis, N., Hepatitis C virus infection and risk of coronary artery disease: a systematic review of the literature. Clin Physiol Funct Imaging 32:6 (2012), 421–430.
11. [11] Maruyama, S., Koda, M., Oyake, N., Sato, H., Fujii, Y., Horie, Y., et al. Myocardial injury in patients with chronic hepatitis C infection. J Hepatol 58:1 (2013), 11–15.
12. [12] Mostafa, A., Mohamed, M.K., Saeed, M., Hasan, A., Fontanet, A., Godsland, I., et al. Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors. Gut 59:8 (2010), 1135–1140.
13. [13] Adinolfi, L.E., Restivo, L., Zampino, R., Guerrera, B., Lonardo, A., Ruggiero, L., et al. Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. Atherosclerosis 221:2 (2012), 496–502.
14. [14] Boddi, M., Abbate, R., Chellini, B., Giusti, B., Giannini, C., Pratesi, G., et al. Hepatitis C virus RNA localization in human carotid plaques. J Clin Virol 47:1 (2010), 72–75.
15. [15] Olubamwo, O.O., Onyeka, I.N., Miettola, J., Kauhanen, J., Tuomainen, T.P., Hepatitis C as a risk factor for carotid atherosclerosis – a systematic review. Clin Physiol Funct Imaging 36 (2016), 249–260.
16. [16] He, H., Kang, R., Zhao, Z., Hepatitis C virus infection and risk of stroke: a systematic review and meta-analysis. PLoS ONE, 8(11), 2013, e81305.
17. [17] Huang, H., Kang, R., Zhao, Z., Is hepatitis C associated with atherosclerotic burden? A systematic review and meta-analysis. PLOS ONE, 9(9), 2014, e106376.
18. [18] Negro, F., Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases. J Hepatol 61:1 Suppl (2014), S69–S78.
19. [19] Guiltinan, A.M., Kaidarova, Z., Custer, B., Orland, J., Strollo, A., Cyrus, S., et al. Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors. Am J Epidemiol 167:6 (2008), 743–750.
20. [20] Butt, A.A., Xiaoqiang, W., Budoff, M., Leaf, D., Kuller, L.H., Justice, A.C., Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis 49:2 (2009), 225–232.
21. [21] Freiberg, M.S., Chang, C.C., Skanderson, M., McGinnis, K., Kuller, L.H., Kraemer, K.L., et al. The risk of incident coronary heart disease among veterans with and without HIV and hepatitis C. Circ Cardiovasc Qual Outcomes 4:4 (2011), 425–432.
22. [22] Lin, M.S., Guo, S.E., Chen, M.Y., Huang, T.J., Huang, J.C., Hu, J.H., et al. The impact of hepatitis C infection on ischemic heart disease via ischemic electrocardiogram. Am J Med Sci 347:6 (2014), 478–484.
23. [23] Pothineni, N.V., Delongchamp, R., Vallurupalli, S., Ding, Z., Dai, Y., Hagedorn, C.H., et al. Impact of hepatitis C seropositivity on the risk of coronary heart disease events. Am J Cardiol 114:12 (2014), 1841–1845.
24. [24] Chew, K.W., Bhattacharya, D., McGinnis, K., Horwich, T.B., Tseng, C.H., Currier, J., et al. Coronary heart disease risk by Framingham risk score in hepatitis C and HIV/hepatitis C coinfected persons. AIDS Res Hum Retroviruses 31 (2015), 718–722.
25. [25] Lee, M.H., Yang, H.I., Wang, C.H., Jen, C.L., Yeh, S.H., Liu, C.J., et al. Hepatitis C virus infection and increased risk of cerebrovascular disease. Stroke 41:12 (2010), 2894–2900.
26. [26] Hsu, Y.H., Muo, C.H., Liu, C.Y., Tsai, W.C., Hsu, C.C., Sung, F.C., et al. Hepatitis C virus infection increases the risk of developing peripheral arterial disease: a 9-year population-based cohort study. J Hepatol 62:3 (2015), 519–525.
27. [27] Khot, U.N., Khot, M.B., Bajzer, C.T., Sapp, S.K., Ohman, E.M., Brener, S.J., et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 290:7 (2003), 898–904.
28. [28] Bielinski, S.J., Berardi, C., Decker, P.A., Kirsch, P.S., Larson, N.B., Pankow, J.S., et al. P-selectin and subclinical and clinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 240:1 (2015), 3–9.
29. [29] Fletcher, N.F., Wilson, G.K., Murray, J., Hu, K., Lewis, A., Reynolds, G.M., et al. Hepatitis C virus infects the endothelial cells of the blood–brain barrier. Gastroenterology 142:3 (2012), 634–643.
30. [30] Roed, T., Kristoffersen, U.S., Knudsen, A., Wiinberg, N., Lebech, A.M., Almdal, T., et al. Increased prevalence of coronary artery disease risk markers in patients with chronic hepatitis C—a cross-sectional study. Vasc Health Risk Manag 10 (2014), 55–62.
31. [31] Ferroni, P., Mammarella, A., Martini, F., Paoletti, V., Cardarello, C.M., Labbadia, G., et al. Increased soluble P-selectin levels in hepatitis C virus-related chronic hepatitis: correlation with viral load. J Investig Med 49:5 (2001), 407–412.
32. [32] Satoh, K., Nagano, T., Seki, N., Tomita, Y., Aida, Y., Sugita, T., et al. High level of serum cholesteryl ester transfer protein in active hepatitis C virus infection. World J Hepatol 8:5 (2016), 291–300.
33. [33] Barter, P.J., Rye, K.A., Cholesteryl ester transfer protein inhibition is not yet dead-pro. Arterioscler Thromb Vasc Biol 36:3 (2016), 439–441.
34. [34] Nicholls, S.J., Ruotolo, G., Brewer, H.B., Wang, M.D., Liu, L., Willey, M.B., et al. Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients. J Clin Lipidol 10:3 (2016), 519–527.
35. [35] McLain, J.H., Alsterda, A.J., Arora, R.R., Cholesteryl ester transfer protein inhibitors: trials and tribulations. J Cardiovasc Pharmacol Ther(August), 2016 pii:1074248416662349.
36. [36] Serfaty, L., Capeau, J., Hepatitis C, insulin resistance and diabetes: clinical and pathogenic data. Liver Int 29:Suppl 2 (2009), 13–25.
37. [37] Schnier, C., Wild, S., Kurdi, Z., Povey, C., Goldberg, D.J., Hutchinson, S.J., Matched population-based study examining the risk of type 2 diabetes in people with and without diagnosed hepatitis C virus infection. J Viral Hepat 23 (2016), 596–605.
38. [38] Petta, S., Maida, M., Macaluso, F.S., Barbara, M., Licata, A., Craxi, A., et al. Hepatitis C virus infection is associated with increased cardiovascular mortality: a meta-analysis of observational studies. Gastroenterology 150:1 (2016), 145–155.
39. [39] Jung, H.J., Kim, Y.S., Kim, S.G., Lee, Y.N., Jeong, S.W., Jang, J.Y., et al. The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients. Clin Mol Hepatol 20:1 (2014), 38–46.
40. [40] Economou, E.K., Oikonomou, E., Siasos, G., Papageorgiou, N., Tsalamandris, S., Mourouzis, K., et al. The role of microRNAs in coronary artery disease: from pathophysiology to diagnosis and treatment. Atherosclerosis 241:2 (2015), 624–633.
41. [41] Lee, C.H., Kim, J.H., Lee, S.W., The role of microRNAs in hepatitis C virus replication and related liver diseases. J Microbiol 52:6 (2014), 445–451.
42. [42] Willeit, P., Skroblin, P., Kiechl, S., Fernandez-Hernando, C., Mayr, M., Liver microRNAs: potential mediators and biomarkers for metabolic and cardiovascular disease?. Eur Heart J, 2016.
43. [43] Zhou, L., Irani, S., Sirwi, A., Hussain, M.M., MicroRNAs regulating apolipoprotein B-containing lipoprotein production. Biochim Biophys Acta, 2016.
44. [44] van der Meer, A.J., Farid, W.R., Sonneveld, M.J., de Ruiter, P.E., Boonstra, A., van Vuuren, A.J., et al. Sensitive detection of hepatocellular injury in chronic hepatitis C patients with circulating hepatocyte-derived microRNA-122. J Viral Hepat 20:3 (2013), 158–166.
45. [45] van der Ree, M.H., van der Meer, A.J., van Nuenen, A.C., de Bruijne, J., Ottosen, S., Janssen, H.L., et al. Miravirsen dosing in chronic hepatitis C patients results in decreased microRNA-122 levels without affecting other microRNAs in plasma. Aliment Pharmacol Ther 43:1 (2016), 102–113.
46. [46] Tsiantoulas, D., Diehl, C.J., Witztum, J.L., Binder, C.J., B cells and humoral immunity in atherosclerosis. Circ Res 114:11 (2014), 1743–1756.
47. [47] Lopes-Virella, M.F., Virella, G., Pathogenic role of modified LDL antibodies and immune complexes in atherosclerosis. J Atheroscler Thromb 20:10 (2013), 743–754.
48. [48] Toubi, E., Gordon, S., Kessel, A., Rosner, I., Rozenbaum, M., Shoenfeld, Y., et al. Elevated serum B-lymphocyte activating factor (BAFF) in chronic hepatitis C virus infection: association with autoimmunity. J Autoimmun 27:2 (2006), 134–139.
49. [49] Sobenin, I.A., Salonen, J.T., Zhelankin, A.V., Melnichenko, A.A., Kaikkonen, J., Bobryshev, Y.V., et al. Low density lipoprotein-containing circulating immune complexes: role in atherosclerosis and diagnostic value. Biomed Res Int, 2014, 2014, 205697.
50. [50] Nilsson, J., Bjorkbacka, H., Fredrikson, G.N., Apolipoprotein B100 autoimmunity and atherosclerosis – disease mechanisms and therapeutic potential. Curr Opin Lipidol 23:5 (2012), 422–428.
51. [51] Andre, P., Komurian-Pradel, F., Deforges, S., Perret, M., Berland, J.L., Sodoyer, M., et al. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol 76:14 (2002), 6919–6928.
52. [52] Scholtes, C., Ramiere, C., Rainteau, D., Perrin-Cocon, L., Wolf, C., Humbert, L., et al. High plasma level of nucleocapsid-free envelope glycoprotein-positive lipoproteins in hepatitis C patients. Hepatology 56:1 (2012), 39–48.
53. [53] Agnello, V., Abel, G., Localization of hepatitis C virus in cutaneous vasculitic lesions in patients with type II cryoglobulinemia. Arthritis Rheum 40:11 (1997), 2007–2015.
54. [54] Woollard, K.J., Immunological aspects of atherosclerosis. Clin Sci (Lond) 125:5 (2013), 221–235.
55. [55] Moore, K.J., Sheedy, F.J., Fisher, E.A., Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol 13:10 (2013), 709–721.
56. [56] Griffith, R.L., Virella, G.T., Stevenson, H.C., Lopes-Virella, M.F., Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes. A possible mechanism of foam cell formation. J Exp Med 168:3 (1988), 1041–1059.
57. [57] Albecka, A., Belouzard, S., Op de Beeck, A., Descamps, V., Goueslain, L., Bertrand-Michel, J., et al. Role of low-density lipoprotein receptor in the hepatitis C virus life cycle. Hepatology 55:4 (2012), 998–1007.
58. [58] Roque-Cuellar, M.C., Sanchez, B., Garcia-Lozano, J.R., Garrido-Serrano, A., Sayago, M., Praena-Fernandez, J.M., et al. Expression of CD81, SR-BI and LDLR in lymphocytes and monocytes from patients with classic and occult hepatitis C virus infection. J Med Virol 84:11 (2012), 1727–1736.
59. [59] Harwood, N.M., Golden-Mason, L., Cheng, L., Rosen, H.R., Mengshol, J.A., HCV-infected cells and differentiation increase monocyte immunoregulatory galectin-9 production. J Leukoc Biol 99:3 (2016), 495–503.
60. [60] Smith-Palmer, J., Cerri, K., Valentine, W., Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. BMC Infect Dis, 15, 2015, 19.
61. [61] Olubamwo, O.O., Aregbesola, A.O., Miettola, J., Kauhanen, J., Tuomainen, T.P., Hepatitis C and risk of coronary atherosclerosis – a systematic review. Public Health 138 (2016), 12–25.
62. [62] Manigold, T., Shin, E.C., Mizukoshi, E., Mihalik, K., Murthy, K.K., Rice, C.M., et al. Foxp3+CD4+CD25+ T cells control virus-specific memory T cells in chimpanzees that recovered from hepatitis C. Blood 107:11 (2006), 4424–4432.
63. [63] Meissner, E.G., Lee, Y.J., Osinusi, A., Sims, Z., Qin, J., Sturdevant, D., et al. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. Hepatology 61:3 (2015), 790–801.
64. [64] Horl, G., Froehlich, H., Ferstl, U., Ledinski, G., Binder, J., Cvirn, G., et al. Simvastatin efficiently lowers small LDL-IgG immune complex levels: a therapeutic quality beyond the lipid-lowering effect. PLOS ONE, 11(2), 2016, e0148210.